First Trust Nasdaq BuyWrite Income ETF (NASDAQ: FTQI)

Latest news for First Trust Nasdaq BuyWrite Income ETF (NASDAQ:FTQI)

First Trust Nasdaq BuyWrite Income ETF

Technology

Consumer Cyclical

Communication Services

Healthcare

Industrials

Consumer Defensive

Financial Services

Other

Energy

Utilities

Real Estate

Basic Materials

The fund will pursue its objective by investing primarily in equity securities listed on U.S. exchanges and by utilizing an option strategy consisting of buying U.S. exchange-traded put options on the Standard & Poors 500 Index (the index) and writing (selling) U.S. exchange-traded covered call options on the index. The call options written by the fund will be a laddered portfolio of call options with expirations of less than one year, written at-the-money to slightly out-of-the-money. The fund is non-diversified.

Apple Inc

Microsoft Corp

Nvidia  Corporation 

Amazon.Com Inc

Broadcom, Inc. (purchase Right At $290.00 Per Share) (5)

Meta Platforms, Inc.

Costco Wholesale Corp.

Alphabet, Inc. (cl A)

Alphabet Class C

Netflix Inc Common Stock Usd 0.001

News

Movers

ASML

FTQI

IRBO

NVDA

SMCI

Arm shares are down nearly 30% over the past five days as earnings from ASML Holdings and Taiwan Semiconductor Manufacturing Company have put pressure on the semiconductor sector. 

What&#39;s Going On With Arm Holdings Stock?

On Friday, Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Anthropic announced an expansion of their strategic partnership, strengthening their collaboration on <a target="_blank" href="https://www.aboutamazon.com/news/aws/amazon-invests-additional-4-billion-anthropic-ai" rel="noreferrer noopener">artificial intelligence advancements</a>. &nbsp;
Anthropic raised&nbsp;an additional $4 billion from Amazon. This deepened alliance builds on Amazon&#8217;s $4 billion investment in Anthropic last year, which positioned Amazon Web Services (AWS) as Anthropic&#8217;s primary cloud provider.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/11/42136902/microsofts-brad-smith-urges-trump-government-to-tackle-growing-cyber-threats" rel="noreferrer noopener">Microsoft&#8217;s Brad Smith Urges Trump Government to Tackle Growing Cyber Threats</a>
OpenAI rival Anthropic has now designated AWS as its primary training partner, utilizing AWS Trainium and Inferentia chips to develop and deploy its next-generation foundation models.
Amazon&#8217;s latest cash investment increased its total funding in Anthropic to $8 billion, while Anthropic confirmed that Amazon remains a minority investor. So far, Anthropic has secured $13.7 billion in venture capital funding, TechCrunch <a target="_blank" href="https://techcrunch.com/2024/11/22/anthropic-raises-an-additional-4b-from-amazon-makes-aws-its-primary-cloud-partner/" rel="noreferrer noopener">cites</a> Crunchbase.
Both companies are committed to advancing Trainium&#8217;s hardware and software capabilities, ensuring optimized performance, security, and privacy for customers leveraging Amazon Bedrock&#8217;s Claude models.
As part of the expanded collaboration, AWS customers will gain early access to fine-tune Anthropic models with their data, offering unique customization capabilities for the new Claude model family.
This exclusive feature aligns with Amazon&#8217;s focus on delivering cutting-edge generative AI solutions through its Bedrock platform.
Amazon Bedrock introduced Anthropic&#8217;s Claude 3.5 Haiku and an upgraded Claude 3.5 Sonnet, showcasing their most advanced AI capabilities. Claude 3.5 Sonnet now includes enhanced agentic features like computer use, outperforming other publicly available models in Anthropic&#8217;s tests.
These innovations continue to drive enterprises such as HackerOne, HUDstats, and Sapio Sciences to adopt anthropopic models.
Matt Garman, AWS CEO, praised the collaboration, stating, &#8220;By continuing to deploy Anthropic models in Amazon Bedrock and collaborating on Trainium chips, we&#8217;ll push the boundaries of generative AI technologies.&#8221;
Anthropic CEO Dario Amodei emphasized the partnership&#8217;s impact, noting, &#8220;Our collaboration with Amazon has been instrumental in bringing Claude&#8217;s capabilities to millions of end users.&#8221;
The U.K.&#8217;s Competition and Markets Authority (CMA) scrutinized Amazon and Anthropic&#8217;s partnership following the Federal Trade Commission&#8217;s inquiry into Amazon&#8217;s <a target="_blank" href="https://www.benzinga.com/news/24/08/40255295/amazons-4b-stake-in-anthropic-under-uk-investigation-for-anti-competitive-concerns" rel="noreferrer noopener">$4 billion investment</a> in September 2023. In September 2024, the CMA <a target="_blank" href="https://www.benzinga.com/m-a/24/09/41067395/amazons-partnership-with-jeff-bezos-backed-anthropic-gets-green-signal-from-uk-competition-watchdog" rel="noreferrer noopener">approved the partnership</a>.
The regulator is examining whether the partnership resembles a merger and whether it could lead to anti-competitive practices within the artificial intelligence sector.
U.K. regulators are also investigating Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) Google&#8217;s $2 billion investment in Anthropic for <a target="_blank" href="https://www.benzinga.com/government/24/10/41528255/googles-2b-investment-in-anthropic-under-scrutiny-uk-opens-competition-inquiry" rel="noreferrer noopener">potential competition concerns</a>.
Price Action: AMZN stock is down 0.12% at $198.15 at the last check on Friday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42120110/alibaba-reshapes-e-commerce-operations-names-jiang-fan-as-unit-ceo" target="_blank" rel="noreferrer noopener">Alibaba Reshapes E-Commerce Operations, Names Jiang Fan as Unit CEO</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

AMZN

GOOG

GOOGL

Amazon Strengthens Anthropic Partnership with $8 Billion AI Investment

Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) shares are moving higher on Friday after the company reported better-than-expected 2024 third-quarter earnings on Thursday <a href="https://www.benzinga.com//node/42125007">after the bell</a>.
What Happened: Gap shares traded about 13% higher on Thursday after the company released earnings. The company&#8217;s earnings report included earnings per share of 72 cents, beating analyst estimates of 57 cents.
In addition, the company reported sales of $3.82 billion, beating analyst estimates of $3.81 billion. The company broke down its sales for the quarter further. Specifically, Gap reported store sales decreased by 2% year-over-year and online sales increased by 7% year-over-year.
Additionally, the company reported net sales of $2.2 billion from Old Navy, $899 million from Gap, $469 million from Banana Republic and $290 million from Athleta.
Furthermore, Gap reported other key pieces of financial data. It reported operating expenses of $1.3 billion and operating income of $355 million. The company said it ended the quarter with $2.2 billion in cash, cash equivalents and short-term investments, a 64% growth compared to the prior year.
&#8220;I&#8217;m proud that Gap Inc. delivered another successful quarter, growing net sales for the 4th&nbsp;consecutive quarter and gaining market share across all brands while meaningfully expanding operating margin,&#8221; said President and CEO,&nbsp;Richard Dickson. 
&#8220;Consistent execution of our strategic priorities, including the rigor and repetition we&#8217;re applying to our brand reinvigoration playbook, is making us a stronger company and demonstrates our continued progress in unlocking Gap Inc.&#8217;s full potential.&#8221;
Gap raised its outlook for the 2024 fiscal year. It now expects revenue to be up 1.5% to 2% and operating income margin in the mid to high 60% range.
Analyst Changes: Following the earnings report, several analysts issued price target adjustments.
<ul>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating on Gap and maintained a $26 price target.</li>
<li>B of A Securities maintained a Neutral rating on Gap and raised the price target from&nbsp;$25&nbsp;to&nbsp;$28.</li>
<li>Morgan Stanley analyst Alex Straton maintained an Overweight rating on Gap and raised the price target from&nbsp;$29&nbsp;to&nbsp;$30.</li>
<li>Barclays analyst Adrienne Yih maintained an Overweight rating on Gap and raised the price target from&nbsp;$31&nbsp;to&nbsp;$32.</li>
<li>Wells Fargo analyst Ike Boruchow maintained an Overweight rating on Gap and raised the price target from&nbsp;$28&nbsp;to&nbsp;$30.</li>
<li>Evercore ISI Group analyst Michael Binetti maintained an Outperform rating on Gap and raised the price target from&nbsp;$32&nbsp;to&nbsp;$33.</li>
</ul>
Related Link: <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full">Nvidia Beats Q3 Revenue, EPS Estimates, Supply Constraints Ding Stock: Huang Says &#8216;Age Of AI Is In Full Steam&#8217; (UPDATED)</a>
GAP Price Action: At the time of writing, Gap shares are trading 9.07% higher at $24.04, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Courtesy of Gap, Inc.

What's Going On With Gap Shares Friday?

Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) stock remained largely unchanged this week as investors digested NVIDIA Corp&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42121215/nvidia-post-earnings-jitters-can-nvda-stock-regain-its-ai-fueled-momentum">third-quarter earnings report</a>.
Nvidia, AMD&#8217;s key competitor in high-performance GPUs and AI hardware, posted solid third-quarter results that beat analyst expectations. However, its guidance for the fourth quarter dampened enthusiasm, leaving some investors cautious about the short-term outlook.
What To Know: Analysts praised Nvidia's performance, noting strong AI demand and a robust product pipeline, particularly around its next-generation Blackwell architecture. 
Cantor Fitzgerald and Piper Sandler analysts emphasized that the Blackwell ramp is outpacing initial expectations, and demand continues to outstrip supply. Despite this, Nvidia's guidance for fourth quarter gross margins and revenue fell short of lofty investor expectations, triggering some profit-taking.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42135905/bitcoin-nears-100000-momentum-could-continue-well-beyond-the-milestone-experts-note">Bitcoin Nears $100,000, &#8216;Momentum Could Continue Well Beyond The Milestone,&#8217; Experts Note</a>
For AMD, the lack of significant movement in its stock price reflects the lingering uncertainty in the sector. While Nvidia solidifies its dominance in AI hardware, AMD has been making inroads with its MI300 chips, targeting similar data center and AI workloads. Investors appear to be awaiting clearer signs of market share gains or a breakout moment for AMD in the competitive AI space.
Nvidia's results serve as a bellwether for the broader semiconductor industry, and the mixed reactions highlight investor sensitivity to future growth prospects amidst a year of outsized gains for AI-related stocks. 
With AMD and Nvidia navigating a rapidly evolving landscape, all eyes remain on product launches and guidance updates in early 2025.
Read Also: <a href="https://www.benzinga.com/news/large-cap/24/11/42094649/nvidia-stock-historically-drops-in-december-after-q3-earnings">Nvidia Stock Historically Drops In December After Q3 Earnings</a>
<h2 class="wp-block-heading">How To Buy AMD Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Advanced Micro Devices&#8217; case, it is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AMD has a 52-week high of $227.30 and a 52-week low of $116.37.

What's Going On With AMD Stock?

WIIM

TMDX

TransMedics shares are trading lower after Needham downgraded the stock from Buy to Hold.

Hidetaka Miyazaki, the director of Elden Ring and president of FromSoftware, apologized to fans for the long wait for the Shadow of the Erdtree DLC while accepting the Best Game Expansion award during the <a href="https://www.benzinga.com/general/gaming">Golden Joystick Awards.</a> 
In a video message, Miyazaki expressed gratitude to fans for their support and teased that the studio is working on multiple new projects.ç
See Also: <a href="https://www.benzinga.com/general/gaming/24/11/42068231/sony-in-talks-to-acquire-elden-ring-publisher-kadokawa-report">Sony In Talks To Acquire Elden Ring Publisher Kadokawa: Report</a>
&#8220;I must sincerely apologize for the lengthy wait of over two years since the release of the main game to deliver this DLC,&#8221; Miyazaki said. 
He called the award an "incredible honor" and thanked players for their patience and dedication. "Receiving such a prestigious reward brings me great relief, and I am deeply thankful to all the players who enjoyed and supported the main game and the DLC."
<h3 class="wp-block-heading">FromSoftware Has New Projects In Development</h3>
"We are currently working on various new projects, and I hope you will look forward to what we have in store next," Miyazaki said.
However, he didn't elaborate on what these might be, <a href="https://www.benzinga.com/general/entertainment/24/07/39579853/george-r-r-martin-fuels-rumors-about-elden-ring-movie-or-tv-show">leaving fans to speculate. </a>
In June, Miyazaki admitted that even his own team supports fans&#8217; calls for a PC port of Bloodborne. Speaking to PC Gamer, he jokingly said, &#8220;I know for a fact these guys want a Bloodborne PC port. If I say I want one, I&#8217;ll get in trouble as well. But it&#8217;s nothing I&#8217;m opposed to.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/gaming/24/11/42121273/baldurs-gate-3-sees-more-players-in-2024-than-during-launch-year-heres-why">Baldur&#8217;s Gate 3 Sees More Players In 2024 Than During Launch Year: Here&#8217;s Why</a></li>
</ul>
Photo: Shutterstock

Gaming

General

Elden Ring Creator Hidetaka Miyazaki Teases 'Various New Projects' In Development

Carpenter Technology shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a price target of $200.

CROX

Crocs shares are trading higher after Needham initiated coverage on the stock with a Buy rating and announced a price target of $116.

Piper Sandler analyst Rob Owens maintains Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) with a Overweight and raises the price target from $100 to $130.

Price Target

Analyst Ratings

ESTC

Piper Sandler Maintains Overweight on Elastic, Raises Price Target to $130

PTGX

Protagonist Therapeutics shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

Piper Sandler analyst Kashy Harrison maintains Sunnova Energy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) with a Neutral and lowers the price target from $8 to $4.5.

NOVA

Piper Sandler Maintains Neutral on Sunnova Energy Intl, Lowers Price Target to $4.5

Piper Sandler analyst Kashy Harrison maintains Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) with a Neutral and lowers the price target from $1.5 to $0.3.

STEM

Piper Sandler Maintains Neutral on Stem, Lowers Price Target to $0.3

KRRO

Korro Bio shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

KURA

Kura Oncology shares are trading higher. B of A Securities maintained a Buy rating on the stock.

NGVC

Natural Grocers shares are trading higher after the company reported better-than-expected Q4 financial results and announced a quarterly dividend increase from $0.10 to $0.12.

Piper Sandler analyst Kashy Harrison maintains Shoals Technologies Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) with a Overweight and lowers the price target from $10 to $8.

SHLS

Piper Sandler Maintains Overweight on Shoals Technologies Gr, Lowers Price Target to $8

Piper Sandler analyst Kashy Harrison maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Overweight and lowers the price target from $60 to $47.

Piper Sandler Maintains Overweight on NEXTracker, Lowers Price Target to $47

Shoals Technologies Group shares are trading higher. The company announced its CEO bought $101k worth of stock.

Piper Sandler analyst Kashy Harrison maintains Generac Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNRC#NYSE">GNRC</a>) with a Overweight and raises the price target from $190 to $200.

GNRC

Piper Sandler Maintains Overweight on Generac Hldgs, Raises Price Target to $200

In the latest quarter, 8 analysts provided ratings for Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $110.88, a high estimate of $119.00, and a low estimate of $105.00. Surpassing the previous average price target of $108.88, the current average has increased by 1.84%.
<img src="https://www.benzinga.com/files/images/story/2024/1732291255_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Eastman Chemical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>David Begleiter</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$110.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$119.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Michael Sison</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$118.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$107.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Eastman Chemical. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eastman Chemical compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Eastman Chemical's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Eastman Chemical's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EMN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Eastman Chemical analyst ratings.</a>
<h2>Get to Know Eastman Chemical Better</h2>
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
<h3>Eastman Chemical's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Eastman Chemical displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 8.69%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Materials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.31%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.19%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Eastman Chemical's ROA excels beyond industry benchmarks, reaching 1.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Eastman Chemical's debt-to-equity ratio is below the industry average. With a ratio of 0.89, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Breaking Down Eastman Chemical: 8 Analysts Share Their Views

In the preceding three months, 6 analysts have released ratings for Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Janux Therapeutics, presenting an average target of $80.17, a high estimate of $100.00, and a low estimate of $63.00. This current average has decreased by 8.55% from the previous average price target of $87.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1732291248_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Janux Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeffrey La Rosa</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$63.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Dai</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$69.00</td>
<td>-</td>
</tr>
<tr>
<td>Josh Schimmer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Bradley Canino</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$70.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Janux Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Janux Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Janux Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Janux Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/JANX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Janux Therapeutics analyst ratings.</a>
<h2>All You Need to Know About Janux Therapeutics</h2>
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
<h3>Janux Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Janux Therapeutics's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -82.56% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Janux Therapeutics's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -6391.57%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Janux Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -4.27%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Janux Therapeutics's ROA excels beyond industry benchmarks, reaching -4.05%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.04.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

JANX

Evaluating Janux Therapeutics: Insights From 6 Financial Analysts

First Trust Nasdaq BuyWrite Income ETF declares $0.204 dividend

QYLG: A Buy-Write ETF Keeping Some Growth Potential

First Trust Nasdaq BuyWrite Income ETF declares $0.203 dividend

The correction happening in stocks is 'far from over,' IBKR says

FTQI: Unconvincing Buy-Write ETF

First Trust Nasdaq BuyWrite Income ETF declares monthly distribution of $0.2030

Sacrificing Upside For Income: A Look At FTQI

AAPL

AVGO

COST

JEPQ

MSFT

NFLX

QQQM

QRMI

QYLD

QYLG

SDOW

SPXU

SQQQ

TQQQ

TSLA

UDOW

UPRO

Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) shares are falling Friday after Exane BNP Paribas downgraded the stock <a href="https://www.benzinga.com/news/24/04/38299189/whats-going-on-with-arm-holdings-stock">from Outperform to Neutral</a>.



The Details:



Exane BNP Paribas analyst David O&#8217;Connor <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">downgraded</a> Arm from Outperform to Neutral and announced a $100 price target on the stock.&nbsp;



Arm shares are down nearly 30% over the past five days as earnings from ASML Holdings N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) and Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) have put pressure on <a href="https://www.benzinga.com/markets/equities/24/04/38328610/tsmc-cautions-red-hot-chip-industry-growth-could-cool-amid-declining-automotive-chip-demand">the semiconductor sector</a>.&nbsp;



ASML posted worse-than-expected first-quarter results, and TSMC reduced its outlook for the chip market as it sees consumer weakness persisting which overshadowed the company's Q1 results.



Shares of semiconductor companies are falling as investors consider the latest data and the possibility of reduced revenues as the first-quarter earnings season gets underway. Nvidia Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares are down approximately 10%, and Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares have fallen more than 23% Friday afternoon.&nbsp;



SMCI announced its third-quarter earnings date, but did not provide preliminary estimates as it has in previous quarters. Investors may be speculating the company's earnings could be less than stellar due to the absence of preliminary estimates.&nbsp;



Investors can gain exposure to Arm by purchasing shares of the First Trust Nasdaq BuyWrite Income ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTQI#NASDAQ">FTQI</a>) or the iShares Robotics and Artificial Intelligence Multisector ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRBO#NYSE">IRBO</a>) both of which count Arm among their holdings.&nbsp;



Related News: <a href="https://www.benzinga.com/news/24/04/38341107/whats-going-on-with-nvidias-stock">What&#8217;s Going On With Nvidia&#8217;s Stock?</a>



ARM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Arm Holdings shares are down 17% at $87.04 at the time of publication Friday.



Image:&nbsp;wikimedia commons

What's Going On With Arm Holdings Stock?

Comments

First Trust Nasdaq BuyWrite Income ETF

News

Latest news for First Trust Nasdaq BuyWrite Income ETF (NASDAQ:FTQI)

Friday, April 19, 2024

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga